Statin Therapy and Tendon Disorders

Abstract

The 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase is an enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, a precursor of cholesterol. This enzyme is a target for pharmacological intervention since it acts on cholesterol biosynthesis. At the cellular level, statins inhibit the conversion of HMG-CoA to mevalonic acid, and as a result, inhibit cholesterol synthesis in the liver [2].